TRAUMA — Sales to customers (Note 9)
Johnson & Johnson TRAUMA — Sales to customers (Note 9) increased by 2.5% to $833.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.9%, from $772.00M to $833.00M. Over 4 years (FY 2021 to FY 2025), TRAUMA — Sales to customers (Note 9) shows relatively stable performance with a 2.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market share or higher procedure volumes for trauma-related surgeries, while a decrease may signal competitive pressure or a decline in elective or emergency orthopedic procedures.
Detailed definition
This metric represents the total revenue generated from the sale of medical devices and surgical instruments specificall...
Peer comparison
Comparable to orthopedic trauma revenue reported by peers like Stryker or Zimmer Biomet, often analyzed alongside overall orthopedic market growth rates.
jnj_segment_trauma_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $710.00M | $715.00M | $728.00M | $748.00M | $696.00M | $717.00M | $710.00M | $757.00M | $739.00M | $742.00M | $741.00M | $765.00M | $759.00M | $761.00M | $764.00M | $772.00M | $768.00M | $793.00M | $813.00M | $833.00M |
| QoQ Change | — | +0.7% | +1.8% | +2.7% | -7.0% | +3.0% | -1.0% | +6.6% | -2.4% | +0.4% | -0.1% | +3.2% | -0.8% | +0.3% | +0.4% | +1.0% | -0.5% | +3.3% | +2.5% | +2.5% |
| YoY Change | — | — | — | — | -2.0% | +0.3% | -2.5% | +1.2% | +6.2% | +3.5% | +4.4% | +1.1% | +2.7% | +2.6% | +3.1% | +0.9% | +1.2% | +4.2% | +6.4% | +7.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's trauma — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported trauma — sales to customers (note 9) of $833.00M in Q1 2026.
- How has Johnson & Johnson's trauma — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's trauma — sales to customers (note 9) increased by 7.9% year-over-year, from $772.00M to $833.00M.
- What is the long-term trend for Johnson & Johnson's trauma — sales to customers (note 9)?
- Over 4 years (2021 to 2025), Johnson & Johnson's trauma — sales to customers (note 9) has grown at a 2.2% compound annual growth rate (CAGR), from $2.89B to $3.15B.
- What does trauma — sales to customers (note 9) mean?
- The total revenue earned from selling orthopedic trauma surgical products and fracture management devices.